FDA green-lights lecanemab to treat Alzheimer’s disease By / On January 10, 2023 / At 11:02 pm / In Chemical world 18 Views The developers list an annual price of $26,500 per patient Post navigation Prev PostAgilent will double oligonucleotide capacity Next PostMechanochemistry set to expand availability of organomanganese reagents You May Also Like Glow-in-the-dark proteins offer cheap and fast diagnostic tests On March 23, 2023 | In Chemical world Arsenite-induced necroptosis requires stress granules On March 22, 2023 | In Chemical world European response to US cleantech incentives leaves industry and environmentalists fuming On March 22, 2023 | In Chemical world